Viatris Inc. is a healthcare company operating in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, the rest of Asia, Africa, Latin America, and the Middle East. It operates through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars across therapeutic areas such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, along with support services like diagnostic clinics, educational seminars, and digital tools. It distributes medicines in oral solid doses, injectables, and complex dosage forms through various channels under brands including Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna. Viatris has collaboration agreements with Mapi Pharma Ltd., Revance Therapeutics, Inc., and Theravance Biopharma, Inc. Founded in 1961, it is headquartered in Canonsburg, Pennsylvania.
Viatris lifts guidance and buyback, but pipeline and China doubts weigh
▲
Kidney drug pipeline advances in Japan Viatris reported positive late-stage results for its kidney disease drug in Japan, with a filing planned by end-2026. A new approved product would add future sales beyond its older medicines, supporting the shares.
New clinical win is a genuine future growth driver for VTRS.
▲
Selected to make Merck's HIV prevention pill Merck licensed Viatris and other generics to produce its once-monthly HIV prevention pill for 129 poorer countries, royalty-free. This gives Viatris a future revenue stream and shows it can win big licensing deals.
New licensing deal adds a concrete long-term revenue opportunity.
▲
Raised 2026 guidance and finished big buyback Viatris lifted its 2026 revenue target to $14.75 billion, returned to profit, and completed a $1.15 billion buyback that cut shares by 8.7%. Fewer shares means each remaining share earns more, a direct boost.
Guidance raise and buyback are the core new fundamental positives.
▼
Strong Q2 still met a negative market reaction Second-quarter revenue and profit beat expectations and guidance rose, yet the stock fell as analysts questioned China growth, supply disruptions, and pipeline trial designs. Good numbers alone are not enough while these doubts linger.
Explains the real counterweight keeping the stock under pressure despite good results.
Q3 2026
▲3▼1
Viatris lifts guidance and buyback, but pipeline and China doubts weigh
▲
Kidney drug pipeline advances in Japan Viatris reported positive late-stage results for its kidney disease drug in Japan, with a filing planned by end-2026. A new approved product would add future sales beyond its older medicines, supporting the shares.
New clinical win is a genuine future growth driver for VTRS.
▲
Selected to make Merck's HIV prevention pill Merck licensed Viatris and other generics to produce its once-monthly HIV prevention pill for 129 poorer countries, royalty-free. This gives Viatris a future revenue stream and shows it can win big licensing deals.
New licensing deal adds a concrete long-term revenue opportunity.
▲
Raised 2026 guidance and finished big buyback Viatris lifted its 2026 revenue target to $14.75 billion, returned to profit, and completed a $1.15 billion buyback that cut shares by 8.7%. Fewer shares means each remaining share earns more, a direct boost.
Guidance raise and buyback are the core new fundamental positives.
▼
Strong Q2 still met a negative market reaction Second-quarter revenue and profit beat expectations and guidance rose, yet the stock fell as analysts questioned China growth, supply disruptions, and pipeline trial designs. Good numbers alone are not enough while these doubts linger.
Explains the real counterweight keeping the stock under pressure despite good results.
News & notes movingVTRS
United StatesIreland
VTRS
Zymeworks Closes Theravance Biopharma Acquisition, Guides 2026 Revenue to $278M-$292M
Zymeworks Inc. announced final transaction details and updated 2026 financial guidance following completion of its acquisition of Theravance Biopharma. The deal adds YUPELRI (revefenacin) to Zymeworks' portfolio, giving it a 35% share of net U.S. profits and ex-U.S. royalties through Theravance's collaboration with Viatris; in the first half of 2026, total YUPELRI sales of $133.1 million generated $38.4 million in collaboration revenue for Theravance Biopharma. Zymeworks expects 2026 total revenue of between $278 million and $292 million and 2026 Adjusted EBITDA of between $114 million and $128 million, and it projects a mid-teens base-case IRR supported primarily by YUPELRI growth and a smaller contribution from VIBATIV, with no value assigned to $2.5 billion of Irish tax attributes or to a potential $100 million TRELEGY ELLIPTA milestone payment expected in the first quarter of 2027. Theravance Biopharma shareholders received $17.00 in cash per share at closing, financed by a $350 million non-dilutive, non-recourse note from OMERS, under which 75% of YUPELRI profit-share cash flows are contractually assigned to OMERS, plus approximately $217.5 million of Zymeworks' existing cash. Zymeworks also said it will retain the current commercial organization supporting YUPELRI hospital promotion, named Stuart Knight as Executive Vice President and Chief Information Officer and Jesse Fecker as Vice President, Intellectual Property, and reported that it has used approximately $49.3 million of its $125.0 million 2026 share repurchase authorization to buy 1,971,454 shares at an average price of $25.04.
TBPH · Capital · Positive Theravance shareholders received $17.00 cash per share at closing of the Zymeworks acquisition.
ZYME · Capital · Positive Zymeworks closed the Theravance acquisition, guided 2026 revenue to $278M-$292M and EBITDA to $114M-$128M, and has repurchased ~$49.3M of shares.
OMERS · Capital · Neutral OMERS provided the $350M non-recourse note financing the deal, receiving 75% of YUPELRI profit-share cash flows.
VTRS · Demand · Neutral Viatris is Theravance's YUPELRI collaboration partner with ex-U.S. royalties, but the article gives no new Viatris-specific development.
Viatris sues Novo Nordisk over generic Wegovy patent rights
Viatris has filed a lawsuit against Novo Nordisk in Delaware federal court seeking a ruling that its planned generic version of Wegovy would not infringe the Danish drugmaker's patent rights. Mylan Pharmaceuticals, a Viatris unit, asked the court on Thursday to determine that its generic product would not violate Novo Nordisk's patent covering a method of administering single-dose Wegovy pens for weight loss. Novo Nordisk generated nearly $31 billion last year from its semaglutide-based weight loss medications Wegovy and Ozempic, according to company reports. Generic versions of Wegovy and Ozempic cannot enter the U.S. market until 2032, when Novo Nordisk's patents covering semaglutide, the drugs' active ingredient, expire. Novo Nordisk has previously settled patent lawsuits over proposed Wegovy and Ozempic generics with Mylan and other drugmakers.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▼Competition
Biotech & Genomic Medicine › Biosimilars ▲Regulation
NVO · Regulation · Negative Viatris is challenging Novo Nordisk's Wegovy patent rights in court, threatening its semaglutide franchise that generated nearly $31 billion last year.
VTRS · Regulation · Positive Viatris unit Mylan filed suit seeking a ruling that its planned generic Wegovy would not infringe Novo's patents, potentially opening the US market for its generic.
ANI Pharmaceuticals Leads Q2 Revenue Growth But Guides Weakest
ANI Pharmaceuticals reported second-quarter revenues of $266 million, up 25.9% year on year, beating analysts' expectations by 2.4%, but its full-year revenue guidance slightly missed estimates, making it the weakest guidance update among the four generic pharmaceuticals stocks tracked. The group as a whole beat consensus revenue estimates by 2.6%, with Amphastar Pharmaceuticals posting revenues of $183.9 million, up 5.4% year on year and beating expectations by 2%, while Viatris reported revenues of $3.76 billion, up 4.9% year on year and exceeding expectations by 2.2%, and Amneal reported revenues of $796.2 million, up 9.9% year on year and beating expectations by 3.6%. Despite the strong revenue performance, share prices of the four companies have fallen an average of 5.6% since their latest earnings results, with ANI Pharmaceuticals down 9.1% to $75.12, Viatris down 7.6% to $16.32, Amneal down 8.3% to $17.52, and Amphastar up 2.3% to $20.28.
Viatris Q2 Earnings Call: Five Key Analyst Questions
Viatris reported second-quarter results that beat Wall Street expectations but still drew a negative market reaction. Revenue came in at $3.76 billion versus analyst estimates of $3.68 billion, a 4.9% year-on-year increase, while adjusted EPS of $0.69 beat estimates of $0.60 by 15%. Management raised full-year revenue guidance to $14.75 billion at the midpoint and adjusted EPS guidance to $2.52, a 5% increase. Analysts focused on China's growth durability, e-commerce contribution, selatogrel's trial design, fast-acting meloxicam's commercial potential, manufacturing disruptions, and cenerimod's clinical data. CEO Scott Smith highlighted strong commercial execution in Greater China and higher-margin generics in North America, while supply chain disruptions and lower-margin products in emerging markets weighed on results.
Viatris reported second-quarter revenue of $3.8 billion, up 3.5% operationally, and raised its full-year 2026 guidance across all key metrics. Adjusted EBITDA rose 8% operationally to $1.2 billion, and adjusted EPS grew 9% to $0.69, driven by 16% operational growth in Greater China and strength in North American complex generics. The company now expects 2026 revenue of $14.55 billion to $14.95 billion, adjusted EBITDA of $4.3 billion to $4.5 billion, and adjusted EPS of $2.45 to $2.59, with midpoints raised for all three. Viatris also announced FDA approval of its Gwyn Lo contraceptive patch, a $30 million upfront deal to sell Tyrvaya rights to Harrow, and completion of its Biocon stake sale for $380 million, while warning that Nashik facility disruptions could cut second-half revenue by $100 million to $150 million.
Viatris Fair Value Estimate Lifted to $18.50 After Q1 Results
Simply Wall St has raised its fair value estimate for Viatris to $18.50 per share from $17.94, reflecting updated assumptions after the company's first-quarter results and pipeline progress. The revision incorporates a revenue growth assumption of 1.84%, down from 2.00%, a profit margin expectation of 4.92%, up from 4.50%, a future P/E multiple of 34.43x, down from 36.72x, and a discount rate of 7.24%, up from 7.11%. Separately, Barclays lifted its price target to $22 from $17 and maintained an Overweight rating, citing strong Q1 execution and an expected slate of product approvals this year that could help close the revenue growth gap to peers and support a higher valuation multiple over time.
Viatris wins FDA approval for Gwyn Lo contraceptive patch
Viatris has received U.S. FDA approval for its new combined hormonal contraceptive patch, Gwyn Lo. The product is a low-dose estrogen contraceptive patch with data supporting its efficacy and safety. This approval adds a branded asset to Viatris' women's health portfolio and may influence its U.S. market position. The stock has shown strong momentum, with a share price of $17.56, a 40.9% return year to date, and a 107.2% return over the past year.
StockStory flags Chemed, Bristol-Myers Squibb, and Viatris as healthcare stocks to avoid
StockStory identifies three healthcare stocks that investors should keep off their radar due to weak financial performance. Chemed, with a market cap of $6.65 billion, saw annual revenue growth of just 4% over five years and EPS growth of only 2.8% annually, while its diminishing returns on capital suggest drying profit pools. Bristol-Myers Squibb, valued at $125.6 billion, posted 2.6% annual revenue growth over five years, a 10.4 percentage point drop in adjusted operating margin, and a 1.7% annual EPS decline despite revenue gains. Viatris, with a $20.12 billion market cap, experienced a 2.6% annual sales decline over two years, a 9.2% annual EPS drop over five years, and negative returns on capital indicating value destruction.
Merck unveils early access plan for once-monthly oral HIV prevention pill alimatravir in 129 low- and middle-income countries
Merck announced initial components of a multi-faceted strategy to provide rapid, broad and sustainable access in low- and middle-income countries to alimatravir, an investigational once-monthly oral pill for HIV-1 pre-exposure prophylaxis currently in Phase 3 development. The plan includes seven non-exclusive voluntary licensing agreements with generic manufacturers covering 129 countries that account for the substantial majority of new HIV diagnoses globally, with royalty-free terms for both public and private sectors. For the first time in HIV prevention, these licenses were signed before Phase 3 trial enrollment is complete, and they include three sub-Saharan African manufacturers—Aspen Pharmacare, Quality Chemical Industries, and UCL Kenya—alongside four Indian companies—Aurobindo, Cipla, Emcure, and Viatris. Merck is also investing early in its own manufacturing capacity to supply product after anticipated U.S. approval while licensed generics complete development, and is in active discussions with organizations including Fiocruz to enable rapid availability in Latin America. The access strategy was shaped by years of engagement with the HIV community and global health stakeholders, and Merck expects to provide initial supply until generic manufacturing capacity is established.
Biotech & Genomic Medicine › Antiviral & Infectious-Disease Therapeutics ▼Competition
MRK · Demand · Positive Merck's investigational HIV prevention pill alimatravir is progressing in Phase 3, with early access plan and voluntary licenses, potentially expanding future demand.
Quality Chemical Industries Limited · Demand · Positive Quality Chemical Industries is one of three sub-Saharan African manufacturers included in the licensing agreements, enabling it to produce and supply alimatravir in 129 countries.
VTRS · Demand · Positive Viatris is one of four Indian generic manufacturers selected for non-exclusive voluntary licensing agreements, enabling future production and revenue.
Aspen Pharmacare Holdings Limited · Demand · Positive Aspen Pharmacare is one of three sub-Saharan African manufacturers selected for non-exclusive voluntary licensing agreements, enabling future production and revenue.
Aurobindo Pharma Limited · Demand · Positive Aurobindo Pharma is one of four Indian generic manufacturers selected for non-exclusive voluntary licensing agreements, enabling future production and revenue.
Cipla · Demand · Positive Cipla is one of four Indian generic manufacturers selected for non-exclusive voluntary licensing agreements, enabling future production and revenue.
Presbyopia Market to Reach Nearly USD 18 Billion by 2036
The presbyopia market across seven major markets is forecast to grow from approximately USD 11 billion in 2025 to nearly USD 18 billion by 2036, a compound annual growth rate of 4.9 percent. The United States accounted for about half of the total market in 2025 and is expected to remain the largest region. Presbyopia eye drops generated roughly USD 3 billion across the seven major markets in 2025, reflecting rising demand for noninvasive pharmacological treatments. Eyeglasses represented around half of US presbyopia market revenue in 2022 and are projected to stay the leading treatment category through 2036. The treatment landscape is shifting from conventional optical correction toward prescription therapies, with approved products including VUITY, QLOSI, and YUVEZZ, while late-stage pipeline candidates from Eyenovia, Opus Genetics and Viatris, and Glaukos Corporation may further reshape competition.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
GKOS · Demand · Positive Glaukos has a late-stage pipeline candidate for presbyopia, and the market is forecast to grow to $18B by 2036, indicating rising demand for treatments.
IRD · Demand · Positive Opus Genetics has a late-stage pipeline candidate for presbyopia, and the market is forecast to grow to $18B by 2036, indicating rising demand for treatments.
VTRS · Demand · Positive Viatris has a late-stage pipeline candidate for presbyopia, and the market is forecast to grow to $18B by 2036, indicating rising demand for treatments.
Six Late-Stage Therapies Poised to Reshape the Systemic Lupus Erythematosus Treatment Market
The systemic lupus erythematosus market is at a turning point as six late-stage emerging therapies advance toward potential approval, according to DelveInsight. The market, valued at approximately USD 3 billion in 2025 across the United States, EU4, the United Kingdom, and Japan, is projected to grow at a compound annual growth rate of 10.4% through 2036. Among the highlighted candidates, Biogen and Royalty Pharma's litifilimab has completed enrollment in two Phase III trials with topline results expected in the second half of 2026, while Roche has submitted regulatory applications for obinutuzumab and received FDA acceptance of its supplemental Biologics License Application with a decision anticipated by December 2026. Novartis' ianalumab is in Phase III studies with results expected in 2027 and a potential regulatory submission in 2028, Johnson & Johnson's nipocalimab received Fast Track Designation in March 2026, Idorsia Pharmaceuticals and Viatris' cenerimod is in two Phase III trials and also holds Fast Track Designation, and AbbVie's upadacitinib has advanced to Phase III testing following positive Phase II results.
Three Healthcare Stocks Under $30 With Reaffirmed Guidance and Near-Term Catalysts
Three healthcare stocks trading under $30—Kenvue, Pfizer, and Viatris—offer value setups heading into the second half of 2026. Kenvue, the consumer health company behind Tylenol and Neutrogena, closed at $19.83 and is being acquired by Kimberly-Clark for $3.50 cash plus 0.14625 Kimberly-Clark shares, with shareholder approval secured and the deal expected to close in the second half of 2026. Pfizer trades at $24.32 with a 7.2% dividend yield and a forward P/E of 8, having reaffirmed full-year 2026 revenue guidance of $59.5 to $62.5 billion and adjusted EPS of $2.80 to $3.00, supported by a pipeline that includes roughly 20 pivotal trial starts this year. Viatris, at $16.70, carries a forward P/E of 7 and has three FDA PDUFA decisions due before year-end 2026, while management reaffirmed 2026 guidance and is executing a restructuring targeting $600 to $700 million in annualized cost savings. Each name carries risks including deal execution, patent cliffs, and generic pricing pressure, but all three have reaffirmed 2026 outlooks and identifiable catalysts.
Viatris Secures ¥40 Billion Loan and Reports Positive Phase 3 Results for Nefecon
Viatris entered into a ¥40 billion senior unsecured term loan agreement with a group of lenders led by Mizuho Bank to support general business purposes and refinance an existing loan of the same amount. The loan carries an interest rate based on the TIBO rate plus 1.10%, matures in three years, and is backed by guarantees from key subsidiaries with financial conditions tied to the company's credit ratings. Separately, Viatris reported positive phase 3 results for Nefecon in primary immunoglobulin A nephropathy from a Japanese trial, where the drug met primary and secondary endpoints and reduced urine protein-to-creatinine ratio by about 33.75% after nine months.
Viatris Reports Positive Phase 3 Results for VR-205 in Japanese IgAN Patients
Viatris announced positive top-line results from a Phase 3 clinical trial of VR-205, a targeted-release budesonide, in Japanese adults with primary immunoglobulin A nephropathy. The study met its primary endpoint, showing a statistically significant 33.75% reduction in urine protein-to-creatinine ratio after nine months of treatment, along with improvements in kidney function and sustained proteinuria reduction. The treatment was well tolerated, with no participants progressing to dialysis, kidney transplant, or severe renal impairment. Viatris plans to submit a New Drug Application in Japan by the end of 2026, aiming to make VR-205 the first IgAN-specific targeted-release budesonide oral therapy in the country.
USA
